{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T10:27:51Z","timestamp":1793528871069,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","award":["16LW0239K"],"award-info":[{"award-number":["16LW0239K"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","award":["MSTARS-2"],"award-info":[{"award-number":["MSTARS-2"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euo.2025.12.006","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T20:26:10Z","timestamp":1767126370000},"page":"1066-1079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multiregional Immune Profiling Reveals Prognostic Patterns in Bladder Cancer"],"prefix":"10.1016","volume":"9","author":[{"given":"Nadia","family":"Jurczok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Dernbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Plage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihnea P.","family":"Dragomir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Keyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julika","family":"Ribbat-Idel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Ramberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Ro\u00dfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Schlomm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Klauschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald Bastian","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8601-4598","authenticated-orcid":false,"given":"Marie-Lisa","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Schallenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.12.006_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2025.12.006_b0010","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.21037\/tau.2020.03.13","article-title":"Tumor heterogeneity in muscle-invasive bladder cancer","volume":"9","author":"Kang","year":"2020","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euo.2025.12.006_b0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euo.2025.12.006_b0020","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","volume":"48","author":"Vale","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.006_b0025","doi-asserted-by":"crossref","first-page":"573.e19","DOI":"10.1016\/j.urolonc.2019.06.021","article-title":"Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer","volume":"37","author":"Genitsch","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.006_b0030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12894-020-00733-z","article-title":"Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients","volume":"20","author":"Hamid","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.euo.2025.12.006_b0035","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.3390\/ijms24032160","article-title":"The immune checkpoint landscape in tumor cells of pancreatic ductal adenocarcinoma","volume":"24","author":"Loch","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2025.12.006_b0040","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euo.2025.12.006_b0045","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.12.006_b0050","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.12.006_b0055","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.006_b0060","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.12.006_b0065","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.12.006_b0070","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.12.006_b0075","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.12.006_b0080","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.urolonc.2020.06.007","article-title":"TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer","volume":"40","author":"Attalla","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.006_b0085","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.006_b0090","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-018-0291-4","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibition as a strategy to augment cancer immunotherapy","volume":"32","author":"Yentz","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.euo.2025.12.006_b0095","doi-asserted-by":"crossref","first-page":"810.e17","DOI":"10.1016\/j.urolonc.2019.05.005","article-title":"Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer","volume":"37","author":"Tsai","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.006_b0100","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.4049\/jimmunol.172.9.5450","article-title":"Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo","volume":"172","author":"Workman","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.euo.2025.12.006_b0105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.euo.2025.12.006_b0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000651","article-title":"Stromal LAG-3+ cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture","volume":"8","author":"Zeng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2025.12.006_b0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.euo.2025.12.006_b0120","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.2174\/1871530321666210310142141","article-title":"The potential of T cell immunoglobulin and mucin-domain containing-3 (Tim-3) in designing novel immunotherapy for bladder cancer","volume":"21","author":"Mohsenzadegan","year":"2021","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.euo.2025.12.006_b0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.euo.2025.12.006_b0130","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.euo.2025.12.006_b0135","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA is an immune checkpoint molecule for human T cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2025.12.006_b0140","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12885-023-11157-x","article-title":"Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer","volume":"23","author":"Li","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2025.12.006_b0145","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1007\/s00262-021-02906-7","article-title":"Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancer","volume":"70","author":"Seo","year":"2021","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.euo.2025.12.006_b0150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2024.01.023","article-title":"Prognostic impact and spatial interplay of immune cells in urothelial cancer","volume":"86","author":"Debatin","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.006_b0155","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12894-024-01482-z","article-title":"PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors","volume":"24","author":"Plage","year":"2024","journal-title":"BMC Urol"},{"key":"10.1016\/j.euo.2025.12.006_b0160","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10238-019-00572-9","article-title":"The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis","volume":"19","author":"Wen","year":"2019","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.euo.2025.12.006_b0165","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.12.006_b0170","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.clgc.2015.07.007","article-title":"Outcome of muscle-invasive urothelial bladder cancer after radical cystectomy","volume":"14","author":"Salama","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.12.006_b0175","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.juro.2006.03.038","article-title":"Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era","volume":"176","author":"Hautmann","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.12.006_b0180","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.12.006_b0185","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.euros.2023.03.019","article-title":"International opinions on grading of urothelial carcinoma: a survey among European Association of Urology and International Society of Urological Pathology members","volume":"52","author":"Beijert","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.12.006_b0190","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euf.2018.01.003","article-title":"Grading of urothelial carcinoma and the new \u201cWorld Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016\u201d","volume":"5","author":"Comp\u00e9rat","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.12.006_b0195","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2025.12.006_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2024.152267","article-title":"PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: a comparative study","volume":"69","author":"Paliogiannis","year":"2024","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.euo.2025.12.006_b0205","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4939-7234-0_5","article-title":"Molecular subtype profiling of urothelial carcinoma using a subtype-specific immunohistochemistry panel","volume":"1655","author":"Sj\u00f6dal","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.euo.2025.12.006_b0210","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.euf.2023.03.012","article-title":"Intratumoral heterogeneity of molecular subtypes in muscle-invasive bladder cancer\u2014an extensive multiregional immunohistochemical analysis","volume":"9","author":"Schallenberg","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.12.006_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100753","article-title":"Spatial expression of HER2, NECTIN4, and TROP-2 in muscle-invasive bladder cancer and metastases: implications for pathological and clinical management","volume":"38","author":"Dernbach","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.euo.2025.12.006_b0220","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","article-title":"TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer","volume":"30","author":"Bessede","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.12.006_b0225","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/j.1464-410X.2010.10020.x","article-title":"FOXP3 and survival in urinary bladder cancer","volume":"108","author":"Winerdal","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.12.006_b0230","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00345-015-1615-3","article-title":"The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer","volume":"34","author":"Horn","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.12.006_b0235","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.euo.2025.12.006_b0240","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12967-023-03949-3","article-title":"Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis","volume":"21","author":"Koll","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.euo.2025.12.006_b0245","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23849","article-title":"TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer","volume":"2","author":"Sakuishi","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.euo.2025.12.006_b0250","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.euo.2024.10.004","article-title":"En bloc versus conventional transurethral resection of bladder tumors: a systematic review and meta-analysis of oncological, histopathological, and surgical outcomes","volume":"8","author":"Basile","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.006_b0255","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2025.12.006_b0260","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41419-024-06837-w","article-title":"The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies","volume":"15","author":"Yu","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.euo.2025.12.006_b0265","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00262-022-03309-y","article-title":"PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma","volume":"72","author":"Mocan","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.euo.2025.12.006_b0270","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","article-title":"Intratumoral heterogeneity in cancer progression and response to immunotherapy","volume":"27","author":"Vitale","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.12.006_b0275","unstructured":"Alber M, Tietz S, Dippel J, et al. Atlas: a novel pathology foundation model by Mayo Clinic, Charit\u00e9, and Aignostics. arXiv preprint. https:\/\/doi.org\/10.48550\/arXiv.2501.05409."},{"key":"10.1016\/j.euo.2025.12.006_b0280","unstructured":"Dippel J, Feulner B, Winterhoff T, et al. RudolfV: a foundation model by pathologists for pathologists. arXiv preprint. https:\/\/doi.org\/10.48550\/arXiv.2401.04079."},{"key":"10.1016\/j.euo.2025.12.006_b0285","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s00345-022-04017-z","article-title":"Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2019","volume":"40","author":"Flegar","year":"2022","journal-title":"World J Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125003335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125003335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:32:55Z","timestamp":1793525575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125003335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2588931125003335"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.12.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiregional Immune Profiling Reveals Prognostic Patterns in Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}